Siltuximab vs placebo or usual care
All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether siltuximab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).
1 finding from 1 review
- Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes onlyRR 1.58 [0.74, 3.38]1 study · 148 participantsVery low